Prellis Biologics, founded in the San Francisco Bay Area, focuses on advancing holographic tissue printing technology and immune system applications. Their core mission is to revolutionize therapeutic drug discovery and development by leveraging human immune system biology. The company offers the Externalized Immune System (EXIS™) platform, which facilitates antibody discovery, immunogenicity testing, and vaccine screening. Prellis Biologics aims to transform the biotech landscape by providing innovative solutions for faster and more accurate drug development.

Notable affiliations include collaborations with major pharmaceutical companies like Sanofi and Bristol Myers Squibb. The company has secured significant investment, including a Series C funding round to further its mission. Key achievements include the development of the EXIS™ platform and strategic partnerships that enhance its research capabilities. Overall, Prellis Biologics has made a substantial impact on the biotech industry by accelerating therapeutic discoveries and improving drug development processes.